INTRODUCTION 45
Newly approved antiviral drugs rely upon dosage, treatment period, and drug 46 combinations established during clinical trials. Trials require large cohorts of patients, 47 significant cost, extensive time and strict management of ethics and compliance: 48 Different dose regimens, treatment times and drug combinations are evaluated 49 during trials (1, 2). Additional trials are needed to establish drug efficacy against 50 different viral genotypes (3-6). Despite the significant effort placed in clinical trials, 51 escalation of dosage, increased treatment period, and combination therapy, 52 significant improvement in efficacy have not always been realized. 53
Drug concentrations which achieve 50% virus reduction ( 50 ), can be used to 54 characterize drug activity. Lower 50 means that antiviral effects are achieved with 55 lower concentrations of drug (7); however, a lower 50 does not necessarily 56 translate to higher antiviral effect. Antiviral effect depends on the Hill coefficient ( ), 57 in addition to 50 . A higher value exponentially increases antiviral activity at 58 higher doses (8) (9) (10) (11) (12) (13) (14) . We have previously shown that is unique to each anti-59 hepatitis C virus (HCV) drug, and that augmentation of antiviral activity with 60 escalation of drug dose is quite diverse among the types of anti-HCV drugs (14) . 61
Multidrug treatments also result in diverse effects depending on the drug 62 combination. In-depth profiling of drug antiviral effects can be useful in designing a 63 treatment protocol with maximal antiviral efficacy. Such profiling could result in 64 significant savings in clinical trials. To date, antiviral efficacy variances between 65 different anti-HCV drugs and drug combinations has not been characterized in detail. quantitative method could also support evaluation of next generation anti-HCV 75 treatments that could lead to the eradication of HCV. In the current study, we 76 compare antiviral profiles of different classes of anti-HCV drugs to understand 77 diversity of effects. 78
We recently developed a cell culture system combined with a mathematical 79 model for quantifying anti-HCV drug efficacy at any concentration and multidrug 80 combination (14). We systematically evaluated and compared the intrinsic anti-HCV 81 activity of 15 antiviral agents and their combinations against HCV genotype 1. In the 82 current study, we evaluate intrinsic anti-HCV activity in both genotype 1 and 2. We 83 create an "effectiveness" ranking for HCV replication inhibition in mono-and multi-84 drug cultures following exposure to high drug dose ranges. Significant diversity was 85 observed between the antiviral activity profiles of different drugs. Thus, it is 86 necessary to carefully select multidrug combinations to increase drug efficacy. We 87 have demonstrated that the developed ranking index is able to delineate the 88 advantages of past first-in-line anti-HCV treatment choices (14). Thus, in the current 89 study, we use the combined cell culture plus mathematical modeling approach to 90 quantify efficacy of diverse antiviral drug combinations. This framework could be 91 applied to other diseases requiring multidrug treatment, such as tuberculosis and 92 cancer. 93
RESULTS

94
Fig.1A provides a schematic of the combined experimental and mathematical 95 system that we previously developed for quantifying anti-HCV activity of drug(s) (14) . 96
In the previous study 14 anti-HCV agents were evaluated in mono and combination 97 treatments against HCV genotype 1 (18). In the current study the same 14 drugs 98
( Table 1) were tested against HCV genotype 1 ( Fig.1B) 
Ranking anti-HCV mono-drug treatments 111
As shown in Fig.1B & 1C , the antiviral profile of drugs against HCV genotypes 112 1 and 2 vary widely, suggesting that anti-HCV drugs exhibit strain-dependent effects. 113
The typical dose-response curves of a single antiviral drug can be analyzed using 114 .
(1)
Here, represents the fraction of infection events unaffected by the drug (i.e., 1 − 116 equals the fraction of drug-affected events). is the drug concentration, 50 is the 117 drug concentration that achieves 50% inhibition of activity, and is the slope of the 118 dose-response curve (i.e., Hill coefficient) (14). Dose-response curves for drugs with 119 higher values show stronger antiviral activity at the same normalized drug 120 concentration so long as the drug concentration is higher than 50 (Fig.1D ). Least-121 square regression analysis was used to fit Eq.(1) to dose-response curves ( Fig.1E the dose-response curve at lower drug concentrations ( Fig.1F , especially for doses 125 lower than 50 ). Typical clinical drug concentrations are around 10-to 100-fold of 126 50 , therefore it is generally possible to quantify effectiveness of anti-HCV drug(s) 127 with this method especially for such a high drug concentrations. As discussed in 128 recent publications (8-14), both 50 and values are needed to accurately estimate 129 antiviral drug potency, though only 50 is widely used in the drug development field. 130
Since estimated values for each drug differ relative to target HCV genotype, it is 131 important to optimize mono and combination therapy against each genotype. 132
To characterize efficacy of drugs, we calculated a "required concentration 133 index" (RCI) for each anti-HCV drug against genotype 1 and 2. The RCI represents 134 the critical fold increase of 50 requiring 1 − inhibition of viral replication. 135
(2)
Here, is the critical drug concentration satisfying Eq.
(2). Drugs with small RCI 136 values are more efficient inhibitors of HCV replication than drugs with high RCI. 137
Interestingly, high tends to be associated with smaller RCI. By substituting 138 estimated 50 and parameters and setting to 0.05 in Eq.(2), we calculated the 139 RCI required for 95% inhibition of HCV replication (i.e., RCI 95 ). We summarize RCI 95 140 values of each drug against genotypes 1 and 2 in Fig.2A & 2B , respectively. It 141 should be noted that SOF, a nucleoside-type polymerase inhibitor used as a key 142 agent in current and past DAA combinations, was effective in both genotype 1 and 2, 143 which is consistent with SOF's known clinical pan-genotypic anti-HCV characteristic 144
Ranking anti-HCV multi-drug treatments 147
Using the replicon system, the antiviral activity of double-and triple-drug 148 combinations ( Fig.3 & Fig.4 ) were investigated using consistent ratios of drug 149 concentrations (i.e., 0.25 × 50 , 0.5 × 50 , 1 × 50 , 2 × 50 , and 4 × 50 ). (3)
Here, com is the fraction of infection events unaffected by the drug combination, 160 50 com is the constant ratio that inhibits HCV replication by 50%, and com is the Hill 161 coefficient (14). In Table 2 , we summarize estimated parameters, 50 com and com , 162
Similar to mono treatments, the required concentration index for drug 164 combinations is derived as 165
The RCI required for 95% inhibition of HCV replication is extrapolated from the point 166 at which the curve intersects com = 0.05 (dashed line in The correlation in ranking between the required concentration index and 202 clinical data suggest that this method could assist with the search for drugs that 203 achieve an efficient antiviral inhibition with different HCV genotypes. 204
DISCUSSION
205
Our study shows that the concentration of drug (calculated as fold of 50 ), 206 that achieves 95% virus inhibition (RCI 95 ), highly varied depending on the type of 207 drug and combination with other drugs. RCI 95 of drugs in mono treatment ranged as 208 much as 4.2 fold in antiviral activity against HCV genotype 1 ( Fig In an era of rapidly progressing anti-HCV treatments, selection of the "best" 235 combination treatment is critical to establishing the next generation of anti-HCV 236 treatments against difficult-to-treat HCV and eventually eradicating HCV. We have 237 developed an integrated experimental and mathematical method to evaluate the 238 efficacy of anti-HCV dugs against HCV genotype 1 and 2. The method was used to 239 score mono-and multi-drug treatment regimens against HCV. This scoring could be 240 used to optimize multidrug treatment regimens prior to clinical entry. 241
METHODS
242
Anti-HCV effect of each drug against genotype 1b or genotype 2a was 243 evaluated with subgenomic replicon systems. As a genotype 1b model, LucNeo#2 (CsA) and SCY-635. For multidrug studies, cells were treated with combinations of 264 two or three drugs prior to evaluation of activity. All anti-HCV agents were purchased 265 or kindly provided as described (14) ASV&SOF  ASV&DAS  ASV&LDV  SOF&LDV  DAS&LDV  DAS&DCV  SOF&DAS   a1  a2  a3  a4  a5  a6  a7  a8  a9  a10  a11  a12  a13  a14   RCI   95   0   1   2   3   SOF&LDV&SMV  SOF&DCV&SMV  SOF&DCV&DAS  SOF&LDV&DAS  SOF&DCV&VX  SOF&LDV&VX  SOF&LDV&ASV  SOF&DCV&ASV 
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